A complete list of publications by Dr. Mainga Hamaluba. Use the filters to refine by year, journal or keyword.

No publications match those filters.

1. 2026
   Controlled human malaria infection in adults identify combinations of merozoite antigens associated with clinical immunity

   Ogwang, R. Nkumama, I. N. Mwai, K. Odera, et al.

   Nat Commun. 2026; 17

   View abstract DOI PubMed
2. 2026
   Oral rehydration for severe malnutrition in children with moderate and severe dehydration (GASTROSAM): a phase 2, open-label, superiority randomised controlled trial

   Maitland, K. Sainna, H. Connon, R. Ouattara, et al.

   Lancet Child Adolesc Health. 2026; 10:319-329

   View abstract DOI PubMed
3. 2026
   B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings

   Bundi, C. K. Munoz, O. Kibwana, E. Bellamy, et al.

   Front Immunol. 2026; 17:1743327

   View abstract DOI PubMed
4. 2026
   Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial

   Martinez-de-Albeniz, I. Bottomley, C. Lucinde, R. Kaniu, et al.

   Vaccine. 2026; 73:128186

   View abstract DOI PubMed
5. 2026
   Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial

   Kapulu, M. C. Orenge, F. Kimani, D. Kibwana, et al.

   Nat Med. 2026; 32:178-185

   View abstract DOI PubMed
6. 2026
   A cost-consequence analysis of the children's administration oxygenation strategies trial (COAST) in severe pneumonia

   Carroll, O. U. Grieve, R. Kiguli, S. Olupot-Olupot, et al.

   PLOS Glob Public Health. 2026; 6:e0005654

   View abstract DOI PubMed
7. 2025
   Supplementation with ready-to-use therapeutic food has no effect on adverse outcomes among undernourished children aged 6-59ÔÇ»months with severe pneumonia

   Nalwanga, D. Giallongo, E. Musiime, V. Kiguli, et al.

   Front Nutr. 2025; 12:1507360

   View abstract DOI PubMed
8. 2025
   Pf8: an open dataset of Plasmodium falciparum genome variation in 33,325 worldwide samples

   Malaria Genomic Epidemiology, Network Abdel Hamid, M. M. Abdelraheem, M. H. Acheampong, et al.

   Wellcome Open Res. 2025; 10:325

   View abstract DOI PubMed
9. 2025
   Intravenous Rehydration for Severe Acute Malnutrition with Gastroenteritis

   Maitland, K. Ouattara, S. M. Sainna, H. Chara, et al.

   N Engl J Med. 2025; 393:1257-1268

   View abstract DOI PubMed
10. 2025
    Early weaning from oxygen therapy in African children with severe pneumonia

    Maitland, K. Giallongo, E. Hamaluba, M. Alaroker, et al.

    BMC Med. 2025; 23:366

    View abstract DOI PubMed
11. 2025
    A Pragmatic Trial of Glucocorticoids for Community-Acquired Pneumonia

    Lucinde, R. K. Gathuri, H. Mwaniki, P. Orindi, et al.

    N Engl J Med. 2025; 393:2187-2197

    View abstract DOI PubMed
12. 2022
    A pragmatic randomized controlled trial of standard care versus corticosteroids plus standard care for treatment of pneumonia in adults admitted to Kenyan hospitals (SONIA)

    Lucinde, R. Abdi, A. Orindi, B. Mwakio, et al.

    Wellcome Open Res. 2022; 7:269

    View abstract DOI PubMed
13. 2025
    Investigating the dynamics of Plasmodium falciparum gametocyte carriage in expectant women under intermittent preventive treatment with sulfadoxine-pyrimethamine in Kilifi, study protocol

    Kiyuka, P. K. Muricho, M. Ouma, N. Muiruri, et al.

    Open Res Eur. 2025; 5:60

    View abstract DOI PubMed
14. 2025
    R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial

    Kibwana, E. Bundi, C. Kimani, D. Nyamako, et al.

    Front Immunol. 2025; 16:1620365

    View abstract DOI PubMed
15. 2025
    Vaccine-induced responses to R21/Matrix-M - an analysis of samples from a phase 1b age de-escalation, dose-escalation trial

    Bundi, C. Bellamy, D. Kibwana, E. Nyamako, et al.

    Front Immunol. 2025; 16:1620366

    View abstract DOI PubMed
16. 2025
    COVID-19 mortality in Africa and Asia - Authors' reply

    Bejon, P. Agweyu, A. Oyier, I. Hamaluba, et al.

    Lancet Infect Dis. 2025; 25:e440

    View abstract DOI PubMed
17. 2025
    Rethinking the evidence on COVID-19 in Africa

    Bejon, P. Agweyu, A. Ochola-Oyier, L. I. Hamaluba, et al.

    Lancet Infect Dis. 2025; 25:e463-e471

    View abstract DOI PubMed
18. 2025
    Development of an oral regimen of unithiol for the treatment of snakebite envenoming: a phase 1 open-label dose-escalation safety trial and pharmacokinetic analysis in healthy Kenyan adults

    Abouyannis, M. Nyambura, Y. K. Ngome, S. Riako, et al.

    EBioMedicine. 2025; 113:105600

    View abstract DOI PubMed
19. 2022
    Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial

    Wamae, K. Ndwiga, L. Kharabora, O. Kimenyi, et al.

    Wellcome Open Res. 2022; 7:95

    View abstract DOI PubMed
20. 2024
    Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial

    Schilling, W. H. K. Mukaka, M. Callery, J. J. Llewelyn, et al.

    PLoS Med. 2024; 21:e1004428

    View abstract DOI PubMed
21. 2021
    Gastroenteritis Rehydration Of children with Severe Acute Malnutrition (GASTROSAM): A Phase II Randomised Controlled trial: Trial Protocol

    Olupot-Olupot, P. Aloroker, F. Mpoya, A. Mnjalla, et al.

    Wellcome Open Res. 2021; 6:160

    View abstract DOI PubMed
22. 2024
    Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge

    Nkumama, I. N. Ogwang, R. Odera, D. Musasia, et al.

    Immunity. 2024; 57:1215-1224 e6

    View abstract DOI PubMed
23. 2024
    A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial)

    Maitland, K. Obonyo, N. Hamaluba, M. Ogoda, et al.

    Wellcome Open Res. 2024; 9:281

    View abstract DOI PubMed
24. 2023
    SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART)

    Maitland, K. Hamaluba, M. Obonyo, N. Oguda, et al.

    Wellcome Open Res. 2023; 8:484

    View abstract DOI PubMed
25. 2024
    Nutritional supplementation in children with severe pneumonia in Uganda and Kenya (COAST-Nutrition): a phase 2 randomised controlled trial

    Kiguli, S. Olupot-Olupot, P. Hamaluba, M. Giallongo, et al.

    EClinicalMedicine. 2024; 72:102640

    View abstract DOI PubMed
26. 2024
    Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial

    Gallagher, K. E. Lucinde, R. Bottomley, C. Kaniu, et al.

    N Engl J Med. 2024; 391:2003-2013

    View abstract DOI PubMed
27. 2024
    Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

    Datoo, M. S. Dicko, A. Tinto, H. Ouedraogo, et al.

    Lancet. 2024; 403:533-544

    View abstract DOI PubMed
28. 2023
    Safety and immunogenicity of varied doses of R21/Matrix-M vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya

    Sang, S. Datoo, M. S. Otieno, E. Muiruri, et al.

    Wellcome Open Res. 2023; 8:450

    View abstract DOI PubMed
29. 2023
    Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria

    Odera, D. O. Tuju, J. Mwai, K. Nkumama, et al.

    Sci Transl Med. 2023; 15:eabn5993

    View abstract DOI PubMed
30. 2023
    Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

    Kimathi, D. Juan-Giner, A. Orindi, B. Grantz, et al.

    Lancet Infect Dis. 2023; 23:974-982

    View abstract DOI PubMed
31. 2023
    Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial

    Hamaluba, M. Sang, S. Orindi, B. Njau, et al.

    Wellcome Open Res. 2023; 8:182

    View abstract DOI PubMed
32. 2023
    Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya

    Downs, L. O. Campbell, C. Abouyannis, M. Otiende, et al.

    J Virus Erad. 2023; 9:100355

    View abstract DOI PubMed
33. 2023
    [A global core outcome measurement set for snakebite clinical trials]

    Abouyannis, M. Esmail, H. Hamaluba, M. Ngama, et al.

    Med Trop Sante Int. 2023; 3

    View abstract DOI PubMed
34. 2023
    A long-term observational study of paediatric snakebite in Kilifi County, south-east Kenya

    Abouyannis, M. Boga, M. Amadi, D. Ouma, et al.

    PLoS Negl Trop Dis. 2023; 17:e0010987

    View abstract DOI PubMed
35. 2022
    Is triple artemisinin-based combination therapy necessary for uncomplicated malaria?

    van der Pluijm, R. W. Peto, T. J. Hamaluba, M. Callery, et al.

    Lancet Infect Dis. 2022; 22:765-766

    View abstract DOI PubMed
36. 2022
    Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria

    Musasia, F. K. Nkumama, I. N. Frank, R. Kipkemboi, et al.

    Nature Communications. 2022; 13:4098

    View abstract DOI PubMed
37. 2022
    Undertaking Community Engagement for a Controlled Human Malaria Infection Study in Kenya: Approaches and Lessons Learnt

    Mumba, N. Njuguna, P. Chi, P. Marsh, et al.

    Front Public Health. 2022; 10:793913

    View abstract DOI PubMed
38. 2022
    Controlled human malaria infection (CHMI) outcomes in Kenyan adults is associated with prior history of malaria exposure and anti-schizont antibody response

    Kapulu, M. C. Kimani, D. Njuguna, P. Hamaluba, et al.

    BMC Infect Dis. 2022; 22:86

    View abstract DOI PubMed
39. 2022
    TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults)

    Abouyannis, M. FitzGerald, R. Ngama, M. Mwangudzah, et al.

    Wellcome Open Res. 2022; 7:90

    View abstract DOI PubMed
40. 2021
    Assessing the Level and Determinants of COVID-19 Vaccine Confidence in Kenya

    Orangi, S. Pinchoff, J. Mwanga, D. Abuya, et al.

    Vaccines (Basel). 2021; 9

    View abstract DOI PubMed
41. 2021
    Randomised controlled trial of oxygen therapy and high-flow nasal therapy in African children with pneumonia

    Maitland, K. Kiguli, S. Olupot-Olupot, P. Hamaluba, et al.

    Intensive Care Med. 2021; 47:566-576

    View abstract DOI PubMed
42. 2021
    Children's Oxygen Administration Strategies And Nutrition Trial (COAST-Nutrition): a protocol for a phase II randomised controlled trial

    Kiguli, S. Olopot-Olupot, P. Alaroker, F. Engoru, et al.

    Wellcome Open Res. 2021; 6:221

    View abstract DOI PubMed
43. 2021
    Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial

    Juan-Giner, A. Kimathi, D. Grantz, K. H. Hamaluba, et al.

    Lancet. 2021; 397:119-127

    View abstract DOI PubMed
44. 2021
    Arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial

    Hamaluba, M. van der Pluijm, R. W. Weya, J. Njuguna, et al.

    Lancet Infect Dis. 2021; 21:1395-1406

    View abstract DOI PubMed
45. 2021
    Clinical outcomes and outcome measurement tools reported in randomised controlled trials of treatment for snakebite envenoming: A systematic review

    Abouyannis, M. Aggarwal, D. Lalloo, D. G. Casewell, et al.

    PLoS Negl Trop Dis. 2021; 15:e0009589

    View abstract DOI PubMed
46. 2020
    Deliberately infecting healthy volunteers with malaria parasites: Perceptions and experiences of participants and other stakeholders in a Kenyan-based malaria infection study

    Jao, I. Marsh, V. Che Chi, P. Kapulu, et al.

    Bioethics. 2020; 34:819-832

    View abstract DOI PubMed
47. 2019
    Observational study: 27 years of severe malaria surveillance in Kilifi, Kenya

    Njuguna, P. Maitland, K. Nyaguara, A. Mwanga, et al.

    BMC Med. 2019; 17:124

    View abstract DOI PubMed